Mitochondrial Donation — How Many Women Could Benefit?
CORRESPONDENCE - January 28, 2015
Gráinne S. Gorman, M.D. John P. Grady, Ph.D. Yi Ng, M.D. Andrew M. Schaefer, M.D. Richard J. McNally, Ph.D. Patrick F. Chinnery, Ph.D. Patrick Yu-Wai-Man, Ph.D. Mary Herbert, Ph.D. Robert W. Taylor, Ph.D. Robert McFarland, Ph.D. Doug M. Turnbull, Ph.D.
Author(s) affiliation:
Newcastle University, Newcastle upon Tyne, UK


Short description:
Inherited mutations in mitochondrial DNA (mtDNA) are an important cause of genetic diseases for which there is no effective treatment. New techniques that are based on in vitro fertilization (IVF), including pronuclear and metaphase II spindle transfer,1,2 have the potential to prevent the transmission of serious mtDNA diseases. However, before these techniques are permitted in the United Kingdom, Parliament must agree to new regulations regarding enforcement of the Human Fertilisation and Embryology Act (1990). Central to the debate about the use of these IVF techniques is estimating how many women could potentially benefit from these procedures. This calculation depends on the prevalence of clinically relevant pathogenic mtDNA mutations in the population and the fertility of women with pathogenic mtDNA mutations.
Link to the journal endeavors to ensure that the information in this article is accurate,reliable and up to date. However, the information is provided "as is" without warranty of any kind. IVF-Worldwide does not accept any responsibility or liability for the accuracy,content, completeness, legality, or reliability of the information contained in this article. is not responsible for the content of other websites linked to or referenced from this website. The website does not endorse the information, content,presentation or accuracy of such other websites and does not make any warranty,express or implied, regarding them.